



## PerkinElmer Expands Reagent Portfolio for Faster Identification of Epigenetic Drug Candidates

### PerkinElmer Expands Reagent Portfolio for Faster Identification of Epigenetic Drug Candidates

SAN DIEGO--([BUSINESS WIRE](#))--At the 1<sup>st</sup> annual [Society for Laboratory Automation and Screening](#) Conference in San Diego, [PerkinElmer, Inc.](#), a global leader focused on improving the health and safety of people and the environment, today announced the launch of four new cellular assay kits to help identify and characterize possible drug candidates targeting epigenetic enzymes related to key disease states.

The expansion of the [Epigenetic Biochemical Toolbox](#) increases the portfolio to over 35 validated enzymatic assays for the detection of post-translational modifications of histone H3 and p53. The assays cover all the major writer and eraser enzyme families including HDACs, Sirtuins, HATs, HMTs and demethylases. This newly expanded portfolio helps researchers explore epigenetics-based therapeutic candidates for cancer and neurodegenerative disorders.

"This new addition to our epigenetics portfolio is part of a series of innovations to create a full breadth of offerings to advance personalized medicine research," said Kevin Hrusovsky, president, Life Sciences and Technology, PerkinElmer. "We are taking active steps to continue to transform PerkinElmer into one of the leading providers of technologies, services and products to enable researchers in this expanding market."

The new [AlphaLISA® Epigenetic Cellular Detection Kits](#) enable rapid and direct detection of endogenous modification of epigenetic marks on Histone H3, all in a one-well, no-wash assay format.

"The study of epigenetics is rapidly growing and presents opportunities for drug discovery, resulting in an increased need for high quality reagents," said Mark Roskey, vice president and general manager, Reagents, Life Sciences and Technology, PerkinElmer. "We now provide the most comprehensive reagent portfolio for epigenetic drug discovery. Our solutions are highly validated with detailed, ready-to-use protocols, and optimized for simplicity and throughput, marking our commitment to this expanding area of research."

PerkinElmer's epigenetic portfolio provides researchers access to fully validated reagents and assay development services that offer valuable time savings in the race to discover novel drug candidates. These highly specific reagents along with PerkinElmer's knowledge support for the development of epigenetic assays allow researchers to identify and characterize their lead compounds more quickly and efficiently.

For more information please visit, PerkinElmer during SLAS 2012 at booth number 711 or visit [www.perkinelmer.com/epigenetics](http://www.perkinelmer.com/epigenetics).

#### About PerkinElmer, Inc.

PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The Company reported revenue of approximately \$1.7 billion in 2010, has about 7,000 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at [www.perkinelmer.com](http://www.perkinelmer.com).

#### Contacts

PerkinElmer, Inc.  
Mario Fante, 781-663-5602  
Corporate Public Relations Manager  
[mario.fante@perkinelmer.com](mailto:mario.fante@perkinelmer.com)  
or

Edelman (on behalf of PerkinElmer, Inc.)  
Amanda L. Connolly, 404-832-6785  
[amanda.connolly@edelman.com](mailto:amanda.connolly@edelman.com)